Paper26437366
Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM and 30 others. Nat Med, 2015. Cited by 305 papers, by iCite.
Cite this record
ConductScience Library. Loss of BAP1 function leads to EZH2-dependent transformation. Papers, record 26437366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26437366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Expression Regulation, Neoplastic | Major topic |
| Histones | Major topic |
| Tumor Suppressor Proteins | Major topic |
| Ubiquitin Thiolesterase | Major topic |
| Animals | |
| Blotting, Western | |
| Cell Line, Tumor | |
| Chromatin Immunoprecipitation | |
| Enhancer of Zeste Homolog 2 Protein | |
| Epigenesis, Genetic | |
| Gene Knockout Techniques | |
| HEK293 Cells | |
| Histone Code | |
| Histone-Lysine N-Methyltransferase | |
| Humans | |
| Immunoprecipitation | |
| Leukemia | |
| Mesothelioma | |
| Methylation | |
| Mice | |
| Polycomb Repressive Complex 2 | |
| Real-Time Polymerase Chain Reaction | |
| Repressor Proteins |
Source PubMed
Grants12
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA173636 | NCI NIH HHS | United States | R01CA173636 | PubMed and NIH | NIH RePORTER |
| R01 GM096056 | NIGMS NIH HHS | United States | R01GM096056 | PubMed and NIH | NIH RePORTER |
| F31 CA180642 | NCI NIH HHS | United States | F31CA180642 | PubMed and NIH | NIH RePORTER |
| R01 CA187109 | NCI NIH HHS | United States | R01CA187109 | PubMed and NIH | NIH RePORTER |
| CA172636 | NCI NIH HHS | United States | PubMed | PubMed | |
| 2R01GM096056 | NIGMS NIH HHS | United States | R01GM096056 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| P30 CA060553 | NCI NIH HHS | United States | P30CA060553 | PubMed and NIH | NIH RePORTER |
| R01 GM120570 | NIGMS NIH HHS | United States | R01GM120570 | PubMed and NIH | NIH RePORTER |
| R01 CA169784 | NCI NIH HHS | United States | R01CA169784 | PubMed and NIH | NIH RePORTER |
| UL1 TR000457 | NCATS NIH HHS | United States | UL1TR000457 | PubMed and NIH | NIH RePORTER |
| R01CA176745 | NIH | NIH RePORTER |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 27270772 | Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status. | https://conductscience.org/library/papers/27270772 | PubMed |
| Comment in | 27270773 | Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". | https://conductscience.org/library/papers/27270773 | PubMed |
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22770845 | The polycomb group protein L3mbtl2 assembles an atypical PRC1-family complex that is essential in pluripotent stem cells and early development. | Cell Stem Cell | 2012 | https://conductscience.org/library/papers/22770845 | PubMed |
| 2 | 19388938 | Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. | Br J Haematol | 2009 | https://conductscience.org/library/papers/19388938 | PubMed |
| 3 | 17446892 | Chemical derivatization of histones for facilitated analysis by mass spectrometry. | Nat Protoc | 2007 | https://conductscience.org/library/papers/17446892 | PubMed |
| 4 | 21714648 | Clinical effect of point mutations in myelodysplastic syndromes. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21714648 | PubMed |
| 5 | 22683710 | BAP1 loss defines a new class of renal cell carcinoma. | Nat Genet | 2012 | https://conductscience.org/library/papers/22683710 | PubMed |
| 6 | 21677750 | A conditional knockout resource for the genome-wide study of mouse gene function. | Nature | 2011 | https://conductscience.org/library/papers/21677750 | PubMed |
| 7 | 21051595 | Frequent mutation of BAP1 in metastasizing uveal melanomas. | Science | 2010 | https://conductscience.org/library/papers/21051595 | PubMed |
| 8 | 22878500 | Loss of the tumor suppressor BAP1 causes myeloid transformation. | Science | 2012 | https://conductscience.org/library/papers/22878500 | PubMed |
| 9 | 23680150 | EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. | Cancer Cell | 2013 | https://conductscience.org/library/papers/23680150 | PubMed |
| 10 | 21455215 | Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. | Leukemia | 2011 | https://conductscience.org/library/papers/21455215 | PubMed |
| 11 | 23190500 | Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. | Neuro Oncol | 2013 | https://conductscience.org/library/papers/23190500 | PubMed |
| 12 | 23620515 | Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23620515 | PubMed |
| 13 | 17540172 | L3MBTL1, a histone-methylation-dependent chromatin lock. | Cell | 2007 | https://conductscience.org/library/papers/17540172 | PubMed |
| 14 | 20081860 | Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. | Nat Genet | 2010 | https://conductscience.org/library/papers/20081860 | PubMed |
| 15 | 23051747 | EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. | Nature | 2012 | https://conductscience.org/library/papers/23051747 | PubMed |
| 16 | 20436459 | Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. | Nature | 2010 | https://conductscience.org/library/papers/20436459 | PubMed |
| 17 | 25137013 | Small-molecule inhibitors of SETD8 with cellular activity. | ACS Chem Biol | 2014 | https://conductscience.org/library/papers/25137013 | PubMed |
| 18 | 19233876 | Methylation-state-specific recognition of histones by the MBT repeat protein L3MBTL2. | Nucleic Acids Res | 2009 | https://conductscience.org/library/papers/19233876 | PubMed |
| 19 | 22897849 | ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22897849 | PubMed |
| 20 | 12086618 | PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. | Mol Cell | 2002 | https://conductscience.org/library/papers/12086618 | PubMed |
Cited by230
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 305 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42680845 | Renal cell carcinoma: molecular understanding and therapeutic development. | Cell Death Differ | 2026 | https://conductscience.org/library/papers/42680845 | PubMed |
| 42499709 | Tumor suppressor BAP1 emerges as a key regulator of metabolism and cell death in tumors. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42499709 | PubMed |
| 42295372 | BAP1 loss impairs IFN-γ signaling and enhances NK cell-mediated cytotoxicity in myeloid leukemia. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42295372 | PubMed |
| 42292428 | Molecular mechanisms of KMT2C alterations in gastrointestinal cancers: enhancer network destabilization, lineage plasticity, and clinical translation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292428 | PubMed |
| 42257802 | The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42257802 | PubMed |
| 42150333 | Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42150333 | PubMed |
| 42026135 | Context-dependent synthetic lethality - an emerging precision therapeutic approach. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/42026135 | PubMed |
| 41975017 | Multidisciplinary management of meningiomas in the era of precision oncology. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/41975017 | PubMed |
| 41971442 | From biology to therapy: current standards and emerging strategies in pleural mesothelioma. | Front Oncol | 2026 | https://conductscience.org/library/papers/41971442 | PubMed |
| 41718807 | BRCA1-Associated Protein 1 (BAP1) in Human Cancer and its Emerging Role as a Novel Potential Therapeutic Target. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/41718807 | PubMed |
| 41712014 | Splenic hamartoma in two related patients with BAP1 tumour predisposition syndrome caused by a novel germline BAP1 p.(Gly128Arg) missense variant. | Fam Cancer | 2026 | https://conductscience.org/library/papers/41712014 | PubMed |
| 41670784 | High frequency and unique subtypes of meningioma in patients with BAP1 tumor predisposition syndrome. | J Neurooncol | 2026 | https://conductscience.org/library/papers/41670784 | PubMed |
| 41501212 | BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities. | Oncogene | 2026 | https://conductscience.org/library/papers/41501212 | PubMed |
| 41491589 | Malignant craniopharyngiomas: Institutional experience and literature review. | Brain Pathol | 2026 | https://conductscience.org/library/papers/41491589 | PubMed |
| 41409666 | High Frequency and Unique Subtypes of Meningioma in Patients with BAP1 Tumor Predisposition Syndrome. | medRxiv | 2025 | https://conductscience.org/library/papers/41409666 | PubMed |
| 41377664 | CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated. | iScience | 2025 | https://conductscience.org/library/papers/41377664 | PubMed |
| 41297163 | Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board. | ESMO Open | 2025 | https://conductscience.org/library/papers/41297163 | PubMed |
| 41147157 | Characterization of BRCA1-Associated Protein-1 (BAP1) Aggregation Properties Induced by Cancer-Associated Mutations. | Chembiochem | 2025 | https://conductscience.org/library/papers/41147157 | PubMed |
| 41097640 | EZH2 Dysregulation and Its Oncogenic Role in Human Cancers. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097640 | PubMed |
| 41024086 | Multiple functions of the lysine methyltransferase KMT5a in cancer: potential targets for innovative therapies. | Clin Epigenetics | 2025 | https://conductscience.org/library/papers/41024086 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26437366
GET https://conductscience.org/api/papers/v1/26437366/authors?page=2